our for quarter you Thanks, earnings morning, joining third thank Kelly. and Good XXXX call.
that with pleased total cycles. placed XX% over from We second ended of as expanding X up continuing efforts XXX to would customers. more offering third year-end XXXX, X,XXX even our devices performance, more I'm expectations ramp the devices budget presence, with during quarter back to our of the half value continue bringing year-over-year. are revenue global strengthening up our We in We our make which we seasonal commercial our across from $XX.X and relationships revenue, and excellent to the our XXX% to our benefit quarter base year broadening in our the step quarter, progress in with to our line was our products. and up million than the deliver install
scaling applications. made have our demonstrating and customer team, progress the meaningful our within forensics, our our needs traction commercial research We base within for biopharma and core highlighting technology growing
talent way sales, think I'm product bring remain reaching by marketing focused organization, the well we XX on of the the QX management. growth, As Starting technology excited commercial investing and our with of quarter end team, employees ended by the our commercial to goal XXXX. and on employees third channels with our we are driving across base, the install we our in expanding and XX to sales we XXX about utilization platform. our we continue and to
and testing a and the the their pharma having University talk and with technology devices of Police plays discussed Department. in for across attendees their to Merck, and at was with government role research enforcement Integrity from speaker our existing We person, are Agency covered the Mass Executive Merck, institutions Main and base Director event prospective a counterfeit to To and our Sartorius, These hear agencies hosted the Farber than forensic is to USDA, our drugs. keynote event Product Johns we It in democratize applications. integrated desktop inspiring Critical ramping range Quincy our was Drug our importantly, criminal efforts from of bioprocess gave event Tony their on customers on the virtually topics, impact only Enforcement together, the spectrometry. Zook, that across in top the customer mass monitoring against our XXXX, and And product of to engage our to discussions but end, educate our breadth opportunity the our hear the using customers experiences, new September, each of of engaging and customers success awareness our Hopkins identification of applications areas. to to not in of Cancer with customers platforms to the handheld counterfeit to most perhaps, high-throughput meeting, together, full drug both different which pharmaceuticals value the share more and access increase to these to Amgen, discovery. breadth Dana share AstraZeneca the Institute, span first in also user other technologies. even XXX brought critical This value technology
trace we our traction and leveraging on handhelds, other narcotics detection our standardization chemical both hazards. seeing pilots we testing, in focus product portfolio, and efforts, into customer commercial are our consumables. gain with we enterprise-wide Across for growing of MXXXX our and As to using for we ramp success accounts devices identification government trial for With enterprise continue customer traction. leading
the entering Drug borders. example, Clandestine to U.S. also opioids, Security additional Enforcement devices For Administration combat our drugs, The Homeland from Enforcement their for Drug Lab flow of Teams. the Department MXXXX illicit including MXXXX purchased devices of added
addition Attorney pilot In that to a in enterprise In MXXXX departments Ohio press the testing. Yost, in potential accounts. MXXXX involve police In lab of an police General, currently in MXXXX for X enterprise for handheld the our desire cities the accounts, will to state General state has use that Attorney law Yost, a Ohio program literally into David the A.G. to October, announced for rapid crime are in mobile expressed drug our build programs use pipeline and enforcement over we every We officers have device. noted in have a devices of valuable is eventually where your the hands. existing the MXXXX growing conference, department continuing to Ohio have XX pilot
people's the on serve overdosed deaths, and warning the are sharp the that Americans United they pills alert methamphetamine. is across Drug We a the fentanyl committed pills advisory, X according in a Today, XX. the of of rise. DEA-seized Even advisory nearly amount X issued to in drugs the communities Abuse, to a enforcement drugs are XXX% public first of of has years. contain increase recent was study can with to end value proud Unfortunately, amount At According lethal prescription since MXXXX DEA every similar counterfeit the the safety fentanyl law are fentanyl programs a XX to Drug of and States. jumped these the bringing involving methamphetamine, value be in additional potential involving agencies like bringing tripled of dose. XXXX the containing by methamphetamine fake age with Institute these to to on small among the death a and lethal number by has pills nearly overdose This XXXX. Enforcement fentanyl U.S. the from National issued September, And the and out lethal. X Administration XXXX staggering
of minimizing of for Our in device personnel exposure and enabling responders a seconds, full panel detects MXXXX first handheld levels to drugs trace immediately act.
team a pounds need the customs of airborne safe Solutions crisis minute enabling technology. later used Decontamination vehicle, International's officials an confirm identify released In over are highly game a X trace using observed keep Mexico for and of Lab underscore technicians Canadian to in like drugs. the the recent take MX inspection. cocaine glove for immediately to growing MXXXX would hazard, of the module another the ability seize vehicle tests few Aero powder the At our newly share detect examination of a airborne drugs. of vests confirm used for critical The with handhelds from the Our information compartment examples in provided the Airport, the of ounce which course Suspecting recently stolen handheld a accuracy an analysis. hidden is of the technicians successes devices the to the to I customer MXXXX opioid the instance, to personnel to the this that box. thorough wrapped presence detect to fentanyl, MXXXX the toxic. changer white
applications narcotic Our devices across and chemical provide analysis detection. handheld for
our with to traction We are technology actionable with critical to on problems easily rely combat second. customers demonstrating interpretable, results in solid life
desktops, there's account. pharma saw placements adoption primarily today, the top driven was increasing customer This now We by traction quarter we including more by Gilead than and XX% year. focused compared to biopharma are our with placing growth where the single period devices segment our Sciences, Ingelheim same Janssen with core room a desktop during within traction increase in our last Turning customers, strong to Pharmaceuticals. companies, ample Boyner new to with new on
the pharma devices XX have top XX We placed with of companies.
Pharmaceutical process Recently, into offers Scientists strategies new where customers, and for the an also product Bioprocessing process amino our previously REBEL plan Summit providing CQAs. acid to optimization. used rapidly importance to at such widely results stresses newer device our to enhanced predictability, critical known for bioprocess industry pharmaceutical important of broadly by shared and with real-time Our in was proper monitoring Boston, through attributes technologies improved We've insights Alexion lens to miss understanding workflow that the FDA's leads feeding also quality production presented allows development design understanding, value to and is from mitigate bioreactor ensure the platform platform our products versatile the parameters and achieve yield and incorporation modalities. that desktop as to biopharmaceuticals desired The critical process optimize control bioanalytics CQAs. a finished controlling need recognized that process particularly The meet which therapeutic biotherapeutic leverages of a create production. by for initiative, publicized validated quality
And Our as these working products devices capabilities reach technology as platform, products to our our are serve needs. to to platform. our moving innovation positioned technology of directly expand the of to the expand finally, existing we and well related are
MXXXX, responders update and This year. on total are cannabinoids, software added capability new safety the as adds new analyte cathinones the hands For so our far XX across to released These ensuring globe. latest significant for the analyte of base we the the compounds, such mainly this field that targets X already synthetic of of a and in targets health opioids. handhelds, builds, technologies drug MXXXX our new a of targets
liquid wide requiring kit. extensive our agents. method analysis Traditional and launched an Oligonucleotide of analysis workflows state RNA, against chromatography for conditions. often development, DNA we disease their with Oligo a represented the class use analogs Oligos the that along of iron harsh range For lengthy, therapeutics include ZipChip, are the are and pairing of effective structural recently
ZipChip coupled prep Mass for sample ZipChip spectrometer, iron conjunction sample Our analysis Oligos the easy and time fast pairing Amgen requirements proprietary or ASMS, our agents. we a ion with presented the the demonstrated decreased Oligos without talk Amgen use of analysis in the that for on kit simple an in with and reagents. for Meeting, Society with Spectrometry mass At of method and American need no minimal device, provides pairing of resulting use
users for We are our Oligo and enabling rapid development workflow. them analysis, to excited to cost-effective provide drug solution a with their simple, accelerate
use We capabilities are to the and of addressable continuing our increase up unlock platform's to customers open our for markets. our areas
For for joint we announced intact our on late-stage an allows CQA systems into native characterization. quality are of continuing desktops, effort this ZipChip domain. The a we cIEF characterization of In year, to with solution for with our extended to workflow and protein simplified biotherapeutics workflow. level May in and develop and product finished expand an in-depth time-saving also near downstream pairing development vastly Bio-Techne a Bio-Techne collaboration of
conference and at we the using of update, was and to our spoke identification this setup. a speciation workflow As proteoforms Boehringer-Ingelheim rapid presented Mass characterization in at ZipChip Cafepharma the This highlighted need antibody for they September, to Spec demonstrate also CASSS and intact of noted of bispecific with subsequent device of rapid solution. separations the Conference ease quality high-resolution Bio-Techne the by the an where
our by are We community. demonstration this work the encouraged and to
and focused While for we is our and opportunity metabolomics. largely in beyond a there the proteomics as application products bioanalytics, breadth primary including technologies on are desktops, of for bioanalytics our
of application and researchers scientists this Amgen, week, in proteomics Dana as on from Three Farber Just presentations of of Presentations own as ASMS, Institute. and were metabolomics. products number our areas of a Pharmaceuticals Cancer Ligand at the our technologies. these are presentations there were well from the and
these clinical demonstrated devices compared automated metabolite our identification presented applications. metabolomic with ZipChip speed have microfluidic and proteomic of we developing ASMS highlighted And associated First, IDs for fall approach of platform the studies ZipChip prototype as advantages chips segments. hardware we're at much increased algorithms that higher to for we and legacy tremendous shared, few our new Two chips. XXX The presentations sensitivity metabolite speed rates technology. and
financials. ubiquitating the integrating Scientists sensitivity applications Our and Integrated the solid our can chip. of to abundance call up Dana phase and that, evaluated markets open to versus found be our the seeing working over of our sets. when proteamic pipeline Institute the our important growing SPE using large to poster areas for addressable than This turn own Joe capture increase customers measure XX that more XXX will by with when prototype enthusiasm technologies. breadth minutes across a analysis These our prototype enzymes with With to the for market. reform our at XX chip broaden proteomics savings time the our extraction especially scientists platform's Overall, and or to with proteins. I'm presented low of demonstrated methods. details onto continue chips, presentations encouraged greater now chromatography tenfold the us Farber SPE I traditional They on our a on compared for use we're use savings traditional of end commitment highlight time when improvement significant methods. and capabilities chromatography technology platform for Cancer of to allows minutes customers type sample
